Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone484-380-9263
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees17
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions
What is Madrigal Pharmaceuticals' stock symbol?
Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."
How were Madrigal Pharmaceuticals' earnings last quarter?
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) posted its earnings results on Wednesday, February, 27th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.75). During the same period last year, the company posted ($0.67) EPS. View Madrigal Pharmaceuticals' Earnings History.
When is Madrigal Pharmaceuticals' next earnings date?
What price target have analysts set for MDGL?
14 equities research analysts have issued twelve-month price objectives for Madrigal Pharmaceuticals' stock. Their predictions range from $124.00 to $400.00. On average, they expect Madrigal Pharmaceuticals' share price to reach $232.40 in the next year. This suggests a possible upside of 120.2% from the stock's current price. View Analyst Price Targets for Madrigal Pharmaceuticals.
What is the consensus analysts' recommendation for Madrigal Pharmaceuticals?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Madrigal Pharmaceuticals.
Has Madrigal Pharmaceuticals been receiving favorable news coverage?
Media coverage about MDGL stock has trended positive on Saturday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Madrigal Pharmaceuticals earned a coverage optimism score of 2.7 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future.
Who are some of Madrigal Pharmaceuticals' key competitors?
Some companies that are related to Madrigal Pharmaceuticals include Catalent (CTLT), GALAPAGOS NV/S (GLPG), Amarin (AMRN), Nektar Therapeutics (NKTR), Alkermes (ALKS), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP), Ascendis Pharma A/S (ASND), United Therapeutics (UTHR), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), FibroGen (FGEN) and Evotec (EVTCY).
What other stocks do shareholders of Madrigal Pharmaceuticals own?
Who are Madrigal Pharmaceuticals' key executives?
Madrigal Pharmaceuticals' management team includes the folowing people:
- Dr. Paul A. Friedman, Chairman & CEO (Age 76)
- Dr. Rebecca A. Taub, Founder, Exec. VP of R&D, Chief Medical Officer and Director (Age 67)
- Mr. Marc R. Schneebaum, Sr. VP & CFO (Age 65)
- Mr. Thomas W. Hare, Sr. VP of Clinical Management
Who are Madrigal Pharmaceuticals' major shareholders?
Madrigal Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.18%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc, Fred B Craves, Marc R Schneebaum, Paul A Friedman, Rebecca Taub and Richard S Levy. View Institutional Ownership Trends for Madrigal Pharmaceuticals.
Which institutional investors are buying Madrigal Pharmaceuticals stock?
MDGL stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have bought Madrigal Pharmaceuticals stock in the last two years include Fred B Craves, Paul A Friedman and Richard S Levy. View Insider Buying and Selling for Madrigal Pharmaceuticals.
How do I buy shares of Madrigal Pharmaceuticals?
Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Madrigal Pharmaceuticals' stock price today?
One share of MDGL stock can currently be purchased for approximately $105.56.
How big of a company is Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals has a market capitalization of $1.63 billion. The biopharmaceutical company earns $-32,810,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. Madrigal Pharmaceuticals employs 17 workers across the globe.
What is Madrigal Pharmaceuticals' official website?
How can I contact Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 484-380-9263 or via email at [email protected]
MarketBeat Community Rating for Madrigal Pharmaceuticals (NASDAQ MDGL)
MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote "Outperform" if you believe MDGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
